77 related articles for article (PubMed ID: 26796693)
1. Synthesized peptide 710-725 from HCV subtype 1a E2 glycoprotein blocks HCV infection through competitive binding of CD81.
Liu X; Chen N; Lin S; Liu M
Int J Mol Med; 2016 Mar; 37(3):836-42. PubMed ID: 26796693
[TBL] [Abstract][Full Text] [Related]
2. Identification of peptides that bind hepatitis C virus envelope protein E2 and inhibit viral cellular entry from a phage-display peptide library.
Lü X; Yao M; Zhang JM; Yang J; Lei YF; Huang XJ; Jia ZS; Ma L; Lan HY; Xu ZK; Yin W
Int J Mol Med; 2014 May; 33(5):1312-8. PubMed ID: 24573486
[TBL] [Abstract][Full Text] [Related]
3. A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2.
Yin P; Zhang L; Ye F; Deng Y; Lu S; Li YP; Zhang L; Tan W
Sci Rep; 2017 Jun; 7(1):3976. PubMed ID: 28638089
[TBL] [Abstract][Full Text] [Related]
4. An intramolecular bond at cluster of differentiation 81 ectodomain is important for hepatitis C virus entry.
Yang W; Zhang M; Chi X; Liu X; Qin B; Cui S
FASEB J; 2015 Oct; 29(10):4214-26. PubMed ID: 26116703
[TBL] [Abstract][Full Text] [Related]
5. Selection of peptides binding to HCV e2 and inhibiting viral infectivity.
Hong HW; Lee SW; Myung H
J Microbiol Biotechnol; 2010 Dec; 20(12):1769-71. PubMed ID: 21193836
[TBL] [Abstract][Full Text] [Related]
6. A view of the E2-CD81 interface at the binding site of a neutralizing antibody against hepatitis C virus.
Harman C; Zhong L; Ma L; Liu P; Deng L; Zhao Z; Yan H; Struble E; Virata-Theimer ML; Zhang P
J Virol; 2015 Jan; 89(1):492-501. PubMed ID: 25339761
[TBL] [Abstract][Full Text] [Related]
7. Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner.
McKeating JA; Zhang LQ; Logvinoff C; Flint M; Zhang J; Yu J; Butera D; Ho DD; Dustin LB; Rice CM; Balfe P
J Virol; 2004 Aug; 78(16):8496-505. PubMed ID: 15280458
[TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibition of hepatitis C virus E2 binding to CD81.
VanCompernolle SE; Wiznycia AV; Rush JR; Dhanasekaran M; Baures PW; Todd SC
Virology; 2003 Sep; 314(1):371-80. PubMed ID: 14517089
[TBL] [Abstract][Full Text] [Related]
9. Functional selection of hepatitis C virus envelope E2-binding Peptide ligands by using ribosome display.
Chen F; Zhao Y; Liu M; Li D; Wu H; Chen H; Zhu Y; Luo F; Zhong J; Zhou Y; Qi Z; Zhang XL
Antimicrob Agents Chemother; 2010 Aug; 54(8):3355-64. PubMed ID: 20479194
[TBL] [Abstract][Full Text] [Related]
10. Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry.
Douam F; Dao Thi VL; Maurin G; Fresquet J; Mompelat D; Zeisel MB; Baumert TF; Cosset FL; Lavillette D
Hepatology; 2014 Mar; 59(3):776-88. PubMed ID: 24038151
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles.
Doerrbecker J; Friesland M; Riebesehl N; Ginkel C; Behrendt P; Brown RJ; Ciesek S; Wedemeyer H; Sarrazin C; Kaderali L; Pietschmann T; Steinmann E
Hepatology; 2014 Aug; 60(2):508-20. PubMed ID: 24771613
[TBL] [Abstract][Full Text] [Related]
12. The variable regions of hepatitis C virus glycoprotein E2 have an essential structural role in glycoprotein assembly and virion infectivity.
McCaffrey K; Gouklani H; Boo I; Poumbourios P; Drummer HE
J Gen Virol; 2011 Jan; 92(Pt 1):112-21. PubMed ID: 20926639
[TBL] [Abstract][Full Text] [Related]
13. Ficolin-2 inhibits hepatitis C virus infection, whereas apolipoprotein E3 mediates viral immune escape.
Zhao Y; Ren Y; Zhang X; Zhao P; Tao W; Zhong J; Li Q; Zhang XL
J Immunol; 2014 Jul; 193(2):783-96. PubMed ID: 24928988
[TBL] [Abstract][Full Text] [Related]
14. Interaction of hepatitis C virus envelope glycoprotein E2 with the large extracellular loop of tupaia CD81.
Tian ZF; Shen H; Fu XH; Chen YC; Blum HE; Baumert TF; Zhao XP
World J Gastroenterol; 2009 Jan; 15(2):240-4. PubMed ID: 19132776
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein.
Al Olaby RR; Cocquerel L; Zemla A; Saas L; Dubuisson J; Vielmetter J; Marcotrigiano J; Khan AG; Vences Catalan F; Perryman AL; Freundlich JS; Forli S; Levy S; Balhorn R; Azzazy HM
PLoS One; 2014; 9(10):e111333. PubMed ID: 25357246
[TBL] [Abstract][Full Text] [Related]
16. Two conserved histidines (His490 and His621) on the E2 glycoprotein of hepatitis C virus are critical for CD81-mediated cell entry.
Qin ZL; Ju HP; Gao TT; Wang WB; Ren H; Zhao P; Qi ZT
J Gen Virol; 2015 Jun; 96(Pt 6):1389-1399. PubMed ID: 25701820
[TBL] [Abstract][Full Text] [Related]
17. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor.
Wünschmann S; Medh JD; Klinzmann D; Schmidt WN; Stapleton JT
J Virol; 2000 Nov; 74(21):10055-62. PubMed ID: 11024134
[TBL] [Abstract][Full Text] [Related]
18. Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection.
Zhao X; Tang ZY; Klumpp B; Wolff-Vorbeck G; Barth H; Levy S; von Weizsäcker F; Blum HE; Baumert TF
J Clin Invest; 2002 Jan; 109(2):221-32. PubMed ID: 11805134
[TBL] [Abstract][Full Text] [Related]
19. Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein.
Hung TC; Jassey A; Liu CH; Lin CJ; Lin CC; Wong SH; Wang JY; Yen MH; Lin LT
Phytomedicine; 2019 Feb; 53():62-69. PubMed ID: 30668413
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization.
Falkowska E; Kajumo F; Garcia E; Reinus J; Dragic T
J Virol; 2007 Aug; 81(15):8072-9. PubMed ID: 17507469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
